Clément M L Werner1, Stefan M Zimmermann2, Carola C Würgler-Hauri2, Joseph M Lane3, Guido A Wanner2, Hans-Peter Simmen2. 1. Department of Traumatology, University Hospital, Zurich, Switzerland ; Klinik für Unfallchirurgie, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. 2. Department of Traumatology, University Hospital, Zurich, Switzerland. 3. Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA.
Abstract
BACKGROUND: Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification. One of the involved signaling molecules is platelet-derived growth factor (PDGF) which may be inhibited by imatinib. QUESTIONS/PURPOSES: Our goal was to prevent HO by pharmacologically interfering with the molecular signaling pathways involved in the developmental process. We hypothesized that by administering a proven inhibitor of PDGF expression, heterotopic bone formation may be prevented. METHODS: The effect of imatinib on HO formation was studied in a murine model which reliably produces islets of HO within the soft tissue following Achilles tenotomy. The control group underwent Achilles tenotomy only. The imatinib group received imatinib mesylate. After trial completion, the limbs were harvested and scanned by micro-CT. Heterotopic bone volume was then identified and quantified. RESULTS: The mean volume of heterotopic bone formed in the control group was 0.976mm(3) compared to 0.221 mm(3) in the imatinib group. The volume of HO in the treatment group was reduced by 85% compared to the control group. CONCLUSIONS: The administration of imatinib was associated with a significantly reduced volume of HO. This may be due to the inhibitory effect of imatinib on the PDGF signaling pathway during development of HO. CLINICAL RELEVANCE: The successful reduction of HO formation following imatinib administration has led to further insight concerning the pathogenesis of HO which in the future may lead to new clinical approaches towards the prevention of HO.
BACKGROUND: Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification. One of the involved signaling molecules is platelet-derived growth factor (PDGF) which may be inhibited by imatinib. QUESTIONS/PURPOSES: Our goal was to prevent HO by pharmacologically interfering with the molecular signaling pathways involved in the developmental process. We hypothesized that by administering a proven inhibitor of PDGF expression, heterotopic bone formation may be prevented. METHODS: The effect of imatinib on HO formation was studied in a murine model which reliably produces islets of HO within the soft tissue following Achilles tenotomy. The control group underwent Achilles tenotomy only. The imatinib group received imatinib mesylate. After trial completion, the limbs were harvested and scanned by micro-CT. Heterotopic bone volume was then identified and quantified. RESULTS: The mean volume of heterotopic bone formed in the control group was 0.976mm(3) compared to 0.221 mm(3) in the imatinib group. The volume of HO in the treatment group was reduced by 85% compared to the control group. CONCLUSIONS: The administration of imatinib was associated with a significantly reduced volume of HO. This may be due to the inhibitory effect of imatinib on the PDGF signaling pathway during development of HO. CLINICAL RELEVANCE: The successful reduction of HO formation following imatinib administration has led to further insight concerning the pathogenesis of HO which in the future may lead to new clinical approaches towards the prevention of HO.
Authors: Sofia Jönsson; Bob Olsson; Claes Ohlsson; Mattias Lorentzon; Dan Mellström; Hans Wadenvik Journal: Haematologica Date: 2008-05-27 Impact factor: 9.941
Authors: Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: Don M Ranly; Jacquelyn McMillan; Todd Keller; Christoph H Lohmann; Timothy Meunch; David L Cochran; Zvi Schwartz; Barbara D Boyan Journal: J Bone Joint Surg Am Date: 2005-09 Impact factor: 5.284
Authors: Kate Vandyke; Andrea L Dewar; Peter Diamond; Stephen Fitter; Christopher G Schultz; Natalie A Sims; Andrew C W Zannettino Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Andrea L Dewar; Amanda N Farrugia; Mark R Condina; L Bik To; Timothy P Hughes; Barrie Vernon-Roberts; Andrew C W Zannettino Journal: Blood Date: 2006-01-31 Impact factor: 22.113
Authors: Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino Journal: Blood Date: 2007-11-27 Impact factor: 22.113
Authors: Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore Journal: Curr Osteoporos Rep Date: 2015-04 Impact factor: 5.096
Authors: Haitao Wang; Carter Lindborg; Vitali Lounev; Jung-Hoon Kim; Ruth McCarrick-Walmsley; Meiqi Xu; Laura Mangiavini; Jay C Groppe; Eileen M Shore; Ernestina Schipani; Frederick S Kaplan; Robert J Pignolo Journal: J Bone Miner Res Date: 2016-04-20 Impact factor: 6.741
Authors: Owen G Davies; Yang Liu; Darren J Player; Neil R W Martin; Liam M Grover; Mark P Lewis Journal: Front Physiol Date: 2017-04-03 Impact factor: 4.566
Authors: Philip J Spreadborough; Amy L Strong; John Mares; Benjamin Levi; Thomas A Davis Journal: J Orthop Surg Res Date: 2022-09-19 Impact factor: 2.677
Authors: Stefan M Zimmermann; Lukas W Schwitter; Max J Scheyerer; Thorsten Jentzsch; Hans-Peter Simmen; Clément M L Werner Journal: BMC Surg Date: 2016-05-04 Impact factor: 2.102
Authors: Antonio José Justicia-Grande; Jose Gómez-Ríal; Irene Rivero-Calle; Sara Pischedda; María José Curras-Tuala; Alberto Gómez-Carballa; Miriam Cebey-López; Jacobo Pardo-Seco; Roberto Méndez-Gallart; María José Fernández-Seara; Antonio Salas; Federico Martinón-Torres Journal: Front Pediatr Date: 2021-06-23 Impact factor: 3.418